Glaukos Corporation (GKOS)
NYSE: GKOSHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
GKOS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.16B
- Forward P/E
- 328.86
- EPS (TTM)
- -$3.26
- Dividend yield
- None
- 52-week range
- 73.16 – 191.62
- Day range
- 159.59 – 174.48
- Volume / Avg
- 1.41M / 791.91K
- Beta
- —
- Shares outstanding
- 58.98M
- Next earnings
- Nov 4, 2026
52-week range
GKOS stock today
Shares of Glaukos (GKOS) finished higher on Oct 7 at $172.18, a gain of 6.55% or $10.59 per share, versus the S&P 500's 0.22% decline. At this level, GKOS sits near the top of its 52-week range of $73.16 to $191.62: 10.1% below the high, set on Aug 20, 2026 and 135.3% above the low. GKOS is up 52.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 104.8%.
Glaukos has posted a net loss over the last twelve months (EPS of -$3.26), so its P/E ratio is not meaningful. Glaukos's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Glaukos
Company profileGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Thomas William Burns
- Headquarters
- Aliso Viejo, CA
- Employees
- 1,094
- IPO year
- 2015
- Website
- glaukos.com
Financial highlights
Full financialsIn fiscal 2025, Glaukos generated $507.4 million in revenue, up 32.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Glaukos reported a net loss of $187.7 million, compared with a loss of $146.4 million a year earlier. Gross margin was 55.7% (down from 75.5%) and operating margin -39.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $507.44M | $383.48M | $314.71M | $282.86M | $294.01M |
| Growth | +32.33% | +21.85% | +11.26% | -3.79% | +30.70% |
| Net income | $-187.69M | $-146.37M | $-134.66M | $-99.19M | $-49.59M |
| EPS (diluted) | $-3.28 | $-2.77 | $-2.78 | $-2.09 | $-1.07 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$198.69+15.40%
- Strong buy 3
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.12
- Last reported (Q2 2026)
- Jul 29, 2026
- EPS actual vs est.
- $-0.31 vs —
GKOS news
All GKOS news- Glaukos options flow shows bearish hedge as GKOS rallies 6.6%Investing.com
- Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?NasdaqISRG, EW, GKOS
- Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?NasdaqIDXX, GKOS
- Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?NasdaqISRG, EW, GKOS
Glaukos peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PODDInsulet Corporation | 134.36 | -0.27% | $9.32B | vs GKOS |
| GMEDGlobus Medical Inc. Class A | 73.75 | -3.51% | $9.90B | vs GKOS |
| BAXBaxter International Inc. | 23.97 | -1.60% | $12.39B | vs GKOS |
| PENPenumbra Inc. | 316.35 | -0.22% | $12.46B | vs GKOS |
| MMEDMiniMed Group Inc. | 19.11 | -2.70% | $5.38B | vs GKOS |
| STVNStevanato Group S.p.A. | 19.44 | -2.11% | $5.31B | vs GKOS |
| TFXTeleflex Incorporated | 124.48 | -0.21% | $5.27B | vs GKOS |
| MMSIMerit Medical Systems Inc. | 85.09 | +0.15% | $5.08B | vs GKOS |
Indexes, lists and sector
Glaukos stock FAQ
What is Glaukos's stock price today?
GKOS last traded at $172.18 as of Oct 7, 4:00 PM EDT, up 6.55% on the day. Prices are delayed at least 15 minutes.
When is Glaukos's next earnings date?
Glaukos is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.12.
Who is Glaukos's CEO?
Mr. Thomas William Burns is the chief executive officer of Glaukos Corporation, which has about 1,094 employees.
What is the GKOS 52-week high?
The 52-week high for GKOS is $191.62 and the 52-week low is $73.16. The stock is currently 10.1% below its high.